HHS Launches Initiative To Curb Psychiatric Drug Overuse, Focus On Children
HHS Secretary Robert F. Kennedy Jr. on Monday, May 4, 2026 unveiled an initiative to curb the overuse of psychiatric medications, especially among children. (foxnews.com)
The department sent a letter urging clinicians to prioritize informed consent, shared decision-making and routine reassessment while considering nondrug treatments. The Centers for Medicare and Medicaid Services issued guidance to reimburse physicians who help patients taper psychiatric drugs and monitor withdrawal. The plan also calls for a prescribing-trends report, extra clinician training and an expert panel to shape future policy.
The episode traces back to Kennedy's long-standing advocacy, including the 2011 founding of Children's Health Defense and his public criticism of psychiatric drugs. His views drew attention during an independent 2023 presidential campaign and a 2024 podcast remark about Black children on ADHD medication that drew intense criticism. After endorsing Donald Trump, Kennedy was confirmed as HHS secretary on January 29, 2025 and began pressing the issue publicly in February 2025. That push prompted pushback from medical groups and fed into an October 2025 controversy over substance abuse treatment; in February 2026 he launched a mental health and addiction initiative that committed $100 million to nondrug approaches. Use of SSRIs among U.S. children aged 3-17 rose from 1.5% in 2006 to 3.6% in 2023, and as of 2022 an estimated 11.4% of children aged 3-17 had ever been diagnosed with ADHD. Psychotropic medication use among youth aged 6-24 rose from 5.3% in 2001-2004 to 8.3% in 2017-March 2020.
Mainstream coverage has shifted from reporting Kennedy's skepticism to documenting concrete policy steps like reimbursement changes and a planned prescribing-trends report. Public reaction split online, ranging from praise as a needed check on drug makers to warnings from clinicians that limited access to care, not overprescribing, drives the problem.
The initiative to curb psychiatric drug overuse among children has sparked a polarized discussion online, with many users expressing divergent views on its implications. Health reporter @l_e_whyte highlighted the measures aimed at helping Americans taper off antidepressants, while @Meidas_LaurenA cautioned that the real issue may stem from insufficient access to mental health care rather than overprescribing. This sentiment is echoed by clinicians who argue that limiting prescriptions could exacerbate existing access issues, a perspective that contrasts sharply with the initiative's focus on reducing medication use. Meanwhile, advocates like @AdamI1776 frame the initiative as a necessary stand against pharmaceutical overreach, emphasizing the need for informed consent and safer discontinuation practices for patients.
Data from the U.S. Department of Health and Human Services reveals a significant rise in psychiatric medication use among children, with SSRIs increasing from 1.5% in 2006 to 3.6% in 2023. As of 2022, 11.4% of children aged 3-17 had been diagnosed with ADHD, suggesting a growing reliance on pharmacological interventions. This backdrop of rising mental health issues among youth, as noted in a 2024 PMC article, points to complex societal factors such as academic pressures and social media influence, which may require a more nuanced approach than simply reducing medication prescriptions.
Show source details & analysis (1 source)
📊 Relevant Data
From 2006 to 2023, the annual prevalence of U.S. children and adolescents aged 3-17 years receiving selective serotonin reuptake inhibitors (SSRIs) increased from 1.5% to 3.6%. ([Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services](https://aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents)) ([Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services](https://aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents)) ([Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services](https://aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents)) ([Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services](https://aspe.hhs.gov/reports/psychotropic-medication-among-children-adolescents))
U.S. Population Prevalence of Prescription Psychiatric Medication Among Children and Adolescents — Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services
As of 2022, an estimated 11.4% of U.S. children aged 3–17 years (7.1 million children) have ever been diagnosed with ADHD. ([Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/adhd/data/index.html)) ([Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/adhd/data/index.html)) ([Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/adhd/data/index.html)) ([Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/adhd/data/index.html))
Data and Statistics on ADHD — Centers for Disease Control and Prevention (CDC)
Psychotropic medication use among U.S. youth aged 6-24 increased from 5.3% in 2001-2004 to 8.3% in 2017-March 2020. ([PubMed](https://pubmed.ncbi.nlm.nih.gov/41423041)) ([PubMed](https://pubmed.ncbi.nlm.nih.gov/41423041)) ([PubMed](https://pubmed.ncbi.nlm.nih.gov/41423041)) ([PubMed](https://pubmed.ncbi.nlm.nih.gov/41423041))
📌 Key Facts
- On Monday, May 4, 2026, HHS Secretary Robert F. Kennedy Jr. unveiled an initiative targeting what he described as overuse of psychiatric medications, particularly in children.
- HHS issued a letter urging clinicians to prioritize informed consent, shared decision-making, and routine reassessment of psychiatric medications while considering non-drug treatments.
- CMS announced new guidance allowing reimbursement for physicians who help patients safely taper off psychiatric medications and monitor withdrawal.
- The initiative includes a planned prescribing-trends report, additional clinician training, and an expert panel to inform future policy on psychiatric medication use.
📰 Source Timeline (1)
Follow how coverage of this story developed over time